Literature DB >> 27867593

Duration of dual antiplatelet therapy (DAPT): a call for personalized medicine.

Usman Tahir1, Robert W Yeh1.   

Abstract

Entities:  

Year:  2016        PMID： 27867593      PMCID： PMC5107506          DOI： 10.21037/jtd.2016.10.05

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Authors:  Fausto Feres; Ricardo A Costa; Alexandre Abizaid; Martin B Leon; J Antônio Marin-Neto; Roberto V Botelho; Spencer B King; Manuela Negoita; Minglei Liu; J Eduardo T de Paula; José A Mangione; George X Meireles; Hélio J Castello; Eduardo L Nicolela; Marco A Perin; Fernando S Devito; André Labrunie; Décio Salvadori; Marcos Gusmão; Rodolfo Staico; J Ribamar Costa; Juliana P de Castro; Andrea S Abizaid; Deepak L Bhatt
Journal:  JAMA       Date:  2013-12-18       Impact factor: 56.272

2.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

Authors:  Byeong-Keuk Kim; Myeong-Ki Hong; Dong-Ho Shin; Chung-Mo Nam; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Tae-Soo Kang; Byoung-Eun Park; Woong-Chol Kang; Seung-Hwan Lee; Jung-Han Yoon; Bum-Kee Hong; Hyuck-Moon Kwon; Yangsoo Jang
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

3.  Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.

Authors:  Tomohisa Tada; Robert A Byrne; Iva Simunovic; Lamin A King; Salvatore Cassese; Michael Joner; Massimiliano Fusaro; Simon Schneider; Stefanie Schulz; Tareq Ibrahim; Ilka Ott; Steffen Massberg; Karl-Ludwig Laugwitz; Adnan Kastrati
Journal:  JACC Cardiovasc Interv       Date:  2013-12       Impact factor: 11.195

4.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.

Authors:  Antonio Colombo; Alaide Chieffo; Arian Frasheri; Roberto Garbo; Monica Masotti-Centol; Neus Salvatella; Juan Francisco Oteo Dominguez; Luigi Steffanon; Giuseppe Tarantini; Patrizia Presbitero; Alberto Menozzi; Edoardo Pucci; Josepa Mauri; Bruno Mario Cesana; Gennaro Giustino; Gennaro Sardella
Journal:  J Am Coll Cardiol       Date:  2014-09-15       Impact factor: 24.094

5.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

Review 6.  Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis.

Authors:  Tullio Palmerini; Diego Sangiorgi; Marco Valgimigli; Giuseppe Biondi-Zoccai; Fausto Feres; Alexandre Abizaid; Ricardo A Costa; Myeong-Ki Hong; Byeong-Keuk Kim; Yangsoo Jang; Hyo-Soo Kim; Kyung Woo Park; Andrea Mariani; Diego Della Riva; Philippe Genereux; Martin B Leon; Deepak L Bhatt; Umberto Bendetto; Claudio Rapezzi; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2015-03-24       Impact factor: 24.094

7.  Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.

Authors:  Hyeon-Cheol Gwon; Joo-Yong Hahn; Kyung Woo Park; Young Bin Song; In-Ho Chae; Do-Sun Lim; Kyoo-Rok Han; Jin-Ho Choi; Seung-Hyuk Choi; Hyun-Jae Kang; Bon-Kwon Koo; Taehoon Ahn; Jung-Han Yoon; Myung-Ho Jeong; Taek-Jong Hong; Woo-Young Chung; Young-Jin Choi; Seung-Ho Hur; Hyuck-Moon Kwon; Dong-Woon Jeon; Byung-Ok Kim; Si-Hoon Park; Nam-Ho Lee; Hui-Kyung Jeon; Yangsoo Jang; Hyo-Soo Kim
Journal:  Circulation       Date:  2011-12-16       Impact factor: 29.690

8.  Long-term use of ticagrelor in patients with prior myocardial infarction.

Authors:  Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2015-03-14       Impact factor: 91.245

Review 9.  Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  John A Bittl; Usman Baber; Steven M Bradley; Duminda N Wijeysundera
Journal:  J Am Coll Cardiol       Date:  2016-03-29       Impact factor: 24.094

10.  Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.

Authors:  Francesco Costa; Jan G Tijssen; Sara Ariotti; Sara Giatti; Elisabetta Moscarella; Paolo Guastaroba; Rossana De Palma; Giuseppe Andò; Giuseppe Oreto; Felix Zijlstra; Marco Valgimigli
Journal:  J Am Heart Assoc       Date:  2015-12-07       Impact factor: 5.501
View more
  1 in total

Review 1.  Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.

Authors:  Rahul R Goli; Mayur M Contractor; Ashwin Nathan; Sony Tuteja; Taisei Kobayashi; Jay Giri
Journal:  Curr Atheroscler Rep       Date:  2017-11-04       Impact factor: 5.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.